Parthan, Anju; Kruse, Morgan; Yurgin, Nicole; Huang, Joice - In: Applied Health Economics and Health Policy 11 (2013) 5, pp. 485-497
In each PMO population examined, denosumab represented good value for money compared with branded bisphosphonates. Furthermore, denosumab was either cost effective or dominant compared with generic alendronate in the high-risk subgroups. </AbstractSection> Copyright Springer International Publishing Switzerland 2013
